Glaukos Corp
NYSE:GKOS

  • LAST PRICE
    107.7300
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 107.7300
  • Day Range
    ---
  • 52 Week Range
    54.3801
    113.9700
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Medical Equipment, Supplies & Distribution Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
GKOS
Glaukos Corp
5.5B
-37.4x
---
LNTH
Lantheus Holdings Inc
5.6B
12.4x
+35.30%
INSP
Inspire Medical Systems Inc
4.5B
-300.5x
---
MMSI
Merit Medical Systems Inc
4.8B
47.1x
+14.05%
HAE
Haemonetics Corp
4.7B
39.4x
+17.09%
STVN
Stevanato Group SpA
5.8B
34.9x
---
As of 2024-05-23

Company Information

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.

Contact Information

Headquarters
1 GLAUKOS WAYALISO VIEJO, CA, United States 92656
Phone
949-367-9600
Fax
949-367-9984

Executives

Chairman of the Board, Chief Executive Officer
Thomas Burns
President, Chief Operating Officer
Joseph Gilliam
Chief Financial Officer, Senior Vice President
Alex Thurman
Chief Development Officer
Tomas Navratil
Lead Independent Director
Mark Foley

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$5.4B
Revenue (TTM)
$326.4M
Shares Outstanding
50.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.08
EPS
$-2.88
Book Value
$9.40
P/E Ratio
-37.4x
Price/Sales (TTM)
16.6
Price/Cash Flow (TTM)
---
Operating Margin
-41.29%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.